A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of FT1 in Healthy Adult Volunteers
Latest Information Update: 06 Mar 2026
At a glance
- Drugs FT 1 (Primary)
- Indications Diarrhoea
- Focus Adverse reactions; First in man
- Sponsors Chongqing Peg-Bio Biopharm
Most Recent Events
- 02 Mar 2026 Status changed from recruiting to completed.
- 30 Sep 2024 New trial record